Triple negative breast cancers (TNBCs) are difficult to treat and lack expression of the validated breast cancer therapeutic targets: estrogen (ER), progesterone (PR), and human epidermal growth factor 2 (HER2) receptors1. Here, ERBB2 is linked to breast carcinoma.